Co-Authors
This is a "connection" page, showing publications co-authored by Maurizio Benucci and Luca Quartuccio.
Connection Strength
1.928
-
Old and new antirheumatic drugs for the treatment of COVID-19. Joint Bone Spine. 2020 05; 87(3):195-197.
Score: 0.880
-
Answer to Vieira et al. "Cytokine profile as a prognostic tool in coronavirus disease 2019". Joint Bone Spine 2020. Doi:10.1016/j.jbspin.2020.09.006. Joint Bone Spine. 2021 01; 88(1):105076.
Score: 0.226
-
Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al. Ann Rheum Dis. 2020 Aug 04.
Score: 0.224
-
Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD. Ann Rheum Dis. 2020 Jul 06.
Score: 0.223
-
Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020 05; 87(3):191-193.
Score: 0.220
-
COVID 19: a clue from innate immunity. Immunol Res. 2020 06; 68(3):161-168.
Score: 0.055
-
Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives. Isr Med Assoc J. 2020 04; 22(4):203-210.
Score: 0.055
-
Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clin Exp Rheumatol. 2018 Jan-Feb; 36(1):44-49.
Score: 0.045